Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$3.17 - $6.17 $53,861 - $104,834
16,991 New
16,991 $65,000
Q1 2022

May 16, 2022

SELL
$4.16 - $13.72 $78,528 - $258,992
-18,877 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$10.83 - $18.41 $204,437 - $347,525
18,877 New
18,877 $255,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $219M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Delphia (Usa) Inc. Portfolio

Follow Delphia (Usa) Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Delphia (Usa) Inc., based on Form 13F filings with the SEC.

News

Stay updated on Delphia (Usa) Inc. with notifications on news.